Determinants of vaccination uptake, and influenza vaccine effectiveness in preventing deaths and hospital admissions in the elderly population; Treviso, Italy, 2014/2015-2016/2017 seasons

Stefania Bellino, Cinzia Piovesan, Antonino Bella, Caterina Rizzo, Patrizio Pezzotti, and Mauro Ramigni

ABSTRACT
Seasonal influenza is an important cause of morbidity and mortality, particularly among the elderly population. Determinants of vaccination uptake and its impact on health outcomes in the seasons 2014/2015–2016/2017 in elderly living in Treviso area (Veneto Region, North-Eastern Italy) were evaluated. A retrospective cohort study was conducted combining information from several health administrative databases, and multiple Poisson regression models were applied to evaluate the influenza vaccine effectiveness, also adjusting for confounding factors. MF59-adjuvanted trivalent-inactivated vaccine was mainly administered. Data from more than 83,000 elderly people were analyzed by year. Vaccine coverage was about 50%; influenza vaccination uptake was independently associated with older age, male sex, increasing number of underlying chronic conditions, previous pneumococcal vaccination, annual expenses for specialist medical cares, and general practitioner to whom the elderly was in charge. After adjusting for previously described characteristics, vaccination was associated with lower mortality and influenza-related hospitalization rates. Specifically, during influenza season the adjusted incidence rate ratio of death and of influenza-related hospitalizations for vaccinated compared to unvaccinated persons was 0.63 [95% confidence interval (CI) 0.58–0.69, p < .001] and 0.86 (95% CI 0.81–0.91, p < .001), respectively. A similar effectiveness was estimated for death in all age groups (≤74, 75–84, ≥85 years old), whereas a higher effect was found for hospitalizations in subjects aged ≥75 years old. Vaccination was also effective both in males and females. Findings suggest a health benefit of the influenza vaccination in the elderly population. Efforts should be focused on strategies to increase the vaccination uptake as important instrument of prevention.

Introduction
Influenza is a serious public health problem and a significant source of direct and indirect costs for the implementation of control measures and management of cases and complications. Influenza virus results in annual epidemics, with 3–5 million cases of severe illness worldwide, and 290,000 to 650,000 respiratory deaths, most of them among elderly people, defined as those aged 65 years and older. Furthermore, elderly population, and more specifically those with chronic underlying conditions, are at increased risk for hospitalization due to influenza complications. Indeed, influenza may increase the severity of chronic lung diseases, and viral pneumonia due to influenza seems to predispose to myocardial infarction and congestive heart failures.

Vaccination is currently the most effective measure to prevent influenza or to reduce its morbidity. However, the need of evidence on vaccine effectiveness, its impact, and value across target groups and among seasons continue to generate a large discussion. In addition, evidence of the effectiveness of flu vaccine in preventing severe clinical outcomes was recently described as low or very low among elderly people. As a consequence, despite the Council of the European Union and the World Health Organization (WHO) recommended to annually vaccinate elderly people, influenza vaccine coverage in this group remained below the 75%, target in most European countries. In Italy, a decreasing trend in the vaccine coverage was observed since 2008/09, and in the last seasons, it was around 50% in elderly people, despite the recommendation of the Italian Ministry of Health through the National Vaccination Prevention Plan and the recommendations for influenza prevention published every season.

Another important aspect is that the vaccines developed to protect against seasonal influenza illness are updated every year in an effort to match the influenza A (B) vaccine strain with currently circulating viruses. Indeed, influenza viruses change rapidly due to antigenic drift so that vaccines are reformulated and delivered annually, commonly through seasonal campaigns. Licensed vaccines include inactivated or live-attenuated influenza A (B) strains, with three or four subtypes per vaccine. Since flu vaccines could be less effective in older than in younger adults, due to the weaker immune responses to vaccination for an age-related decline

CONTACT Stefania Bellino
stefania.bellino@iss.it
Department of Infectious Diseases, Istituto Superiore di Sanità, Viale Regina Elena, Rome, 299 – 00161, Italy

© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HUMAN VACCINES & IMMUNOTHERAPEUTICS
2020, VOL. 16, NO. 2, 301–312
https://doi.org/10.1080/21645515.2019.1661754
in immune function, strategies to enhance vaccine immunogenicity and overcome the limitations of immunosenescence include the use of high antigen doses and the formulation of vaccine with an adjuvant.\textsuperscript{13}

Until now, only few studies were performed in Italy, aimed at assessing the effectiveness of influenza vaccination in reducing mortality and hospitalization due to pneumonia or influenza among elderly subjects, with heterogeneous results in terms of percentage of protection,\textsuperscript{14–18} or even no effectiveness.\textsuperscript{19}

In this context, we performed a retrospective cohort study to evaluate the vaccination coverage and its determinants, as well as to estimate the influenza vaccine effectiveness (IVE) in preventing deaths and hospital admissions in the elderly population in a North-Eastern Italian Province of the Veneto Region, during 2014/2015-2016/2017 seasons.

**Methods**

**Setting**

The study refers to people living in the area of Treviso province (Treviso city, and other 36 municipalities, around 400,000 inhabitants, around 90,000 ≥ 65 years old, half of the entire province) in Veneto Region in the North-East of Italy. This is the area covered by the ex-Local Health Unit (LHU) 9 and now part of the LHU called ULSS (Unità Locale Socio Sanitaria) 2 – Marca Trevigiana. LHU is the territorial unit into which Italian National Health Service is divided. In 2017, LHUs in Veneto Region were reorganized, and now the ULSS 2, which covers the entire Treviso province, includes LHU 9 – Treviso, LHU 7 – Pieve di Soligo, and LHU 8 – Asolo.

**Influenza vaccination offer**

Vaccination is offered free of charge to people aged 65 years or older, to other individuals aged 6-months–64 years with specific chronic conditions (such as diabetes, pulmonary and cardiovascular diseases, renal dysfunctions, cancer, immunodeficiency), to pregnant women, to people working in public services, and to healthcare workers. Vaccination campaigns were performed between November 3\textsuperscript{rd} and 28\textsuperscript{th} in 2014, November 9\textsuperscript{th} to December 4\textsuperscript{th} in 2015, and November 14\textsuperscript{th} to December 9\textsuperscript{th} in 2016. A single 0.5 mL dose of MF59-adjuvanted trivalent-inactivated vaccine was usually administered by general practitioners (GP) to their elderly patients. This vaccine has been recommended for adults 65 years and older by local health authority since the early 2000s. GPs are required to return the unused vaccines to the LHU the following week the date of the end of the campaign (28 November, 4 December, 9 December, in 2014, 2015 and 2016, respectively); therefore, all subjects were immunized within mid-december. Moreover, vaccinated subjects were identified by GPs who captured influenza vaccination data (vaccination date and type/brand of vaccine) through a process in which data were initially recorded on paper and subsequently manually entered into a database. However, GP did not always report the exact previous information on vaccination date and vaccine type/brand, therefore he may have used other non-adjuvanted trivalent/quadrivalent vaccines.

**Study design and data sources**

We performed a retrospective cohort study combining information from several health administrative databases from the LHU 9 of the Veneto Region. More specifically, different health electronic databases were linked at the individual level: (1) the influenza vaccination registry, to evaluate whether the individual had been vaccinated before the influenza season start; (2) the Veneto vaccination database, to evaluate if the individual had received pneumococcal vaccination. Pneumococcal vaccination is administered in dedicated LHU vaccination centers (together with all other offered vaccinations except for influenza), and the information is recorded in the Regional Vaccination Registry; (3) the ACG database (Adjusted Clinical Groups, The Johns Hopkins ACG* System) containing information on comorbidities and healthcare resource utilization.\textsuperscript{20,21} In brief, for each individual registered in Veneto Health Care Population Registry (a compulsory registry for receiving universal coverage), data on diagnoses, drugs, procedures and costs were retrieved from the administrative healthcare databases routinely available in the Veneto Region (i.e., Hospital Discharge abstracts, Emergency Room visits, Chronic disease registry for co-payment exemptions, ambulatory visits and medications, and the Home care database). With regard to drug expenditure and usage, only drugs reimbursed by the Regional Health Service were considered, as over-the-counter drug data were not available. Costs were calculated on the basis of a medications’ actual costs and of inpatient/outpatients. The underlying chronic conditions were established using the EDC (Expanded Diagnosis Clusters), which coincides with clinical diagnoses that the ACG System assigns to single patients by combining different information flows as described above; (4) the Regional Hospital Discharge Records, including also hospital admissions in other Italian Regions, to assess dates of hospital admissions, main and secondary clinical diagnoses of discharges and (5) the Mortality database, to obtain date of death. For the latter, specific causes of death were not available; therefore, only death for all-causes was considered as outcome. Moreover, it was not possible to collect information on the laboratory-confirmed influenza cases.

**Statistical analysis**

All people aged ≥65 years old living in the municipalities of the LHU 9, alive at December 15\textsuperscript{th} of each year (2014-2015-2016) were included in the analysis. Residents in long-term care facilities or assigned to a GP out of LHU 9 were excluded from the analysis because it was not possible to establish if they were or not vaccinated for influenza. Analyses were performed both stratifying by season-year and pooling calendar years. Influenza vaccination coverage was calculated as the ratio between vaccinated and exposed elderly in the LHU at December 15\textsuperscript{th} of each year. Data were stratified by the following characteristics: sex, age groups (5-year interval before 90 and ≥90 years old), number of underlying chronic conditions (0, 1, 2, 3, >3), previous pneumococcal vaccination (yes/no), annual expenses for specialist medical care (<300,
300–700, 700–1,700, ≥1,700 Euro, roughly corresponding to the quartile values), and calendar year. Adjusted incidence rate ratios (IRR) of being vaccinated were estimated by a multi-level Poisson regression model, including all the above-mentioned variables. GP was included as a random effect first-level clustering variable; age and sex of the GP were initially included as fixed effect but, given that they were not significantly associated to the outcome, they were not included in the model here reported.

To evaluate the IVE, two outcome measures were considered: mortality rate (all-causes) and hospital admission rate (all-causes and influenza-related) that occurred between December 16, 2014, and December 14, 2017. IVE has been estimated as \((1 - \text{IRR}) \times 100\), where IRR denotes the confounder-adjusted incidence rate ratio, comparing the death/hospitalization incidence rate among the vaccinated subjects to the death/hospitalization incidence rate among the unvaccinated subjects. IVE was evaluated in four different periods: December 15 to March 31 (Influenza season), April 1 to June 30 (post-influenza season), July 1 to September 30 (summer season), October 1 to December 14 (pre-influenza season). We considered this stratification in four periods to test the hypothesis that outside the influenza season no risk difference, in terms of deaths and influenza-related hospitalizations between vaccinated and unvaccinated individuals, should be detected. To define the influenza-related hospitalizations, the following ICD-9-CM (International Classification of Diseases, 9th Revision, Clinical Modification) codes, recorded as primary or secondary diagnoses of discharge, were selected: 487 influenza; 480–486 pneumonia; 460–466, 490–496, 500–508, 510–516 respiratory diseases; 410, 422, 427, 428 cardiovascular diseases; (a detailed description of the diagnoses codes has been reported in Supplementary Table S1).

We considered each hospitalization event unless the same patient experienced readmissions within 3 days after the previous discharge that were due to transfers between hospitals. These re-admissions, being a continuation of a single hospitalization event, were managed accordingly.

To estimate mortality and hospitalization IRR for vaccinated versus unvaccinated, univariable and multivariable Poisson regression models, using clustered sandwich estimator standard error that allows for intra-patient correlation, were applied, including the interaction between vaccination and season-year together with the previously described covariates. Although in the preliminary analyses we considered Poisson multilevel models with GP as a random effect in the final models it was not included because it did not impact the parameter estimates. Regarding the risk of death, the “zero-inflated” Poisson model was applied, given that this provided a significant best fit, as suggested by the Vuong test, compared to the ordinary one. In addition, to evaluate if the estimated IVE on the mortality rates was different by age group (i.e., <75, 75–84, ≥85 years old), sex, and pneumococcal vaccine administration, a “zero inflated” Poisson model with the interaction terms between flu vaccination and sex, age group, and pneumococcal vaccine was also considered, always adjusted for chronic underlying conditions and expenses for medical cares. Same models were applied also to the outcome rate of hospitalization for any cause, and rate of influenza-related hospitalizations; for both outcomes a standard Poisson model, instead of a “zero-inflated” one, was used, because the latter did not add any improvement in the goodness of fit. Finally, to take into account among the potential confounding factors and effect modifiers the influenza vaccination in any of the previous two seasons, a subgroup analysis was performed considering only subjects who contributed to all three cohorts. All models considered as exposure time for each subject the number of days of each period or until the date of death if the subject died before the end of the period, or until the date of change of residence if the person moved to a municipality outside the LHU 9 territory before the end of the period.

All analyses were performed using the Stata software, version 13 (Stata Cooperation, College Station, Texas, USA).

**Results**

The study initially included three cohorts of elderly subjects of 86,724, 83,333, and 89,642 people at December 15 of 2014, 2015, and 2016, respectively. Residents in long-term facilities (2.5% in 2014, 2.4% in 2015, 3.0% in 2016) were excluded from the analysis. Therefore, the evaluated people were 83,265, 83,375, and 85,800 at December 15 of 2014, 2015, and 2016, respectively (see Supplementary Figure S1). Overall, study participants were 93,492, who contributed to at least one cohort year. Specifically, 75,148, 9,652 and 8,692 contributed to three, two and one cohort year, respectively. Person-years during the study period were 125,253 for vaccinated, and 123,752 for unvaccinated.

**Circulating influenza strains and vaccination coverage**

Table 1 shows a summary of the circulating strains overall in Italy and particularly among elderly people in the Veneto Region. In the 2014/15 season, a virus was predominant (84%), with the co-circulation of H1N1 (52%) and H3N2 (41%) subtypes, whereas during the following 2015/16 season, the co-circulation of A (43%; A/H1N1 35%, A/H3N2 56%) and B (57%; Victoria lineage 95%) viruses was observed; finally, in the 2016/17 season the A/H3N2 virus subtype predominated (93%). Regarding the elderly in Veneto Region, there were few differences with the viruses isolated in all population in Italy, except for 2015/16 season, in which a lower percentage of B virus (18%) was detected among elderly. Of note, during 2015/16 and 2016/17 seasons, the influenza B circulating strains at national level were antigenically distinct from those selected for the B component in the trivalent influenza vaccine.

MF59-adjuvanted trivalent inactivated flu vaccine was mainly administered in the elderly living in the LHU 9, during the immunization campaigns although no data were available by type or brand of vaccine; the coverage was around 50% for each year, near to the national value. Pneumococcal vaccination was previously administered in nearly 15% of individuals (most received 23-valent polysaccharide vaccine).

Demographic and clinical characteristics at baseline (December 15th) of each calendar year for vaccinated/unvaccinated people with influenza vaccine are shown in Table 2.
Influenza vaccinated subjects were, on average, older, had more chronic conditions and higher expenses for medical cares, but received less pneumococcal vaccination. In fact, in reference to the latter point, individuals who were not vaccinated with the pneumococcal vaccine received influenza vaccine more frequently than the others (52% vs 43%), particularly if conjugate vaccine PCV13 was not administered. Hypertension, congestive heart failure, metabolic disorders, and asthma were the most represented chronic diseases.

Considering only patients who contributed to all three-cohort years (75,148), 38.2% did not receive any vaccination, 40.9% were vaccinated in all seasons, 11.2% were vaccinated during two seasons, and 9.7% were vaccinated only 1 year. In particular, 89.9% of vaccinated subjects in 2016 received influenza vaccination in at least one of previous two seasons (74.9% received vaccinations in both previous seasons), whereas 84.0% of unvaccinated subjects in 2016 were not previously immunized (data not shown in table).

Both crude and adjusted IRR of being vaccinated were associated with demographic (sex, age groups) and clinical characteristics (number of chronic underlying conditions, previous pneumococcal vaccination, expenses for specialist medical care) (Supplementary Table S2). Specifically, in the multivariable model, the adjusted IRR was higher for males compared to females and for those who received pneumococcal vaccination compared to unvaccinated ones; IRR increased with age, with the number of chronic diseases, and with annual individual health costs. Also GP, as a random effect, was significantly associated with vaccination, and the percentage of vaccinated patients largely varied among them (Supplementary Figure S2). In the model including all three calendar years, an adjusted slightly higher IRR to be vaccinated was detected in 2016/17 as compared to 2014/15 (Supplementary Table S3).

**Risk of death**

There were 8,131 deaths during the study period, 4,855 and 3,276 in vaccinated and unvaccinated subjects, respectively (Supplementary Table S4). Among deaths, the median age was 84 years, and 92% of them had at least one chronic disease. In the unadjusted analysis, vaccinated subjects had significantly higher mortality rates, both during influenza and non-influenza seasons; when adjusting the model for the other confounding factors, vaccination was associated with significant reductions in death (Table 3). Specifically, vaccination had significant estimated reduction of risk of death by 33%, 37%, and 39% (p < .001) during influenza season of 2014/15, 2015/16, and 2016/17, respectively, whereas during the post-influenza season reduction estimates ranged from 17% to 21% (p < .05). Only in the first year, a significant vaccination effect was observed also during summer. Regarding the other characteristics, adjusted IRR of death >1 were detected among males, older individuals, subjects with more chronic conditions and with greater annual expenses for medical cares, while a lower adjusted IRR [0.85, 95% confidence interval (CI) 0.74–0.98, p = .028] was found among pneumococcal vaccine recipients. In the pooled analysis made for all years, the adjusted IRR of death in vaccinated as
Table 2. Vaccination coverage, at December 15th, by demographic and clinical characteristics of the elderly residents in LHU 9, Treviso, Veneto Region, Italy 2014–2016.

|                        | December 15, 2014 | December 15, 2015 | December 15, 2016 |
|------------------------|------------------|------------------|------------------|
|                        | Vaccinated n %    | Unvaccinated n % | Total n %        |
|                        | 41,614 50.0       | 41,651 50.0      | 83,265 100.0     |
|                        | 41,857 49.6       | 42,518 50.4      | 84,375 100.0     |
|                        | 44,250 51.6       | 41,550 48.4      | 85,800 100.0     |
| Participants           |                  |                  |                 |
| Sex                    |                  |                  |                 |
| Female                 | 23,265 49.5       | 23,746 50.5      | 47,011 56.5      |
| Male                   | 18,349 50.6       | 17,905 49.4      | 36,254 43.5      |
| Age group (years)      |                  |                  |                 |
| 65-69                  | 7,096 30.7        | 16,002 69.3      | 23,098 27.7      |
| 70-74                  | 9,339 47.1        | 10,507 52.9      | 19,846 23.8      |
| 75-79                  | 10,000 58.4       | 7,117 41.6       | 17,117 20.6      |
| 80-84                  | 7,649 64.5        | 4,212 35.5       | 11,861 14.2      |
| 85-89                  | 4,923 66.0        | 2,532 34.0       | 7,455 9.0        |
| ≥90                    | 2,607 67.1        | 1,281 32.9       | 3,888 4.7        |
| N. of Clinical conditions |                |                  |                 |
| 0                      | 4,999 30.3        | 11,479 69.7      | 16,478 19.8      |
| 1                      | 11,545 45.9       | 13,613 54.1      | 25,158 30.2      |
| 2                      | 11,134 54.8       | 9,185 45.2       | 20,319 24.4      |
| 3                      | 7,836 62.8        | 4,643 37.2       | 12,479 15.0      |
| 4                      | 6,100 69.1        | 2,731 30.9       | 8,831 10.6       |
| Clinical conditions    |                  |                  |                 |
| Congestive heart failure | 8,549 66.7        | 4,260 33.3       | 12,809 15.4      |
| Ischemic heart disease | 4,341 65.4        | 2,301 34.6       | 6,642 8.0        |
| Hypertension           | 31,995 56.2       | 24,949 43.8      | 56,904 68.3      |
| Metabolic disorders    | 16,858 58.8       | 11,822 41.2      | 28,680 34.4      |
| Diabetes mellitus      | 7,961 61.9        | 4,896 38.1       | 12,857 15.4      |
| COPD                   | 1,294 68.5        | 595 31.5         | 1,889 23.3       |
| Asthma                 | 6,902 61.1        | 4,402 38.9       | 11,304 13.6      |
| Immune deficiency      | 129 52.0          | 119 48.0         | 248 0.3          |
| Rheumatoid arthritis   | 393 51.7          | 367 48.3         | 760 0.9          |
| Renal failure          | 1,134 59.5        | 773 40.5         | 1,907 2.3        |
| Transplant             | 75 38.3           | 121 61.7         | 196 0.2          |
| Pneumococcal vaccination | 5,212 40.9     | 7,547 59.1       | 12,759 15.3      |
| Expenses for specialist medical care (Euros) |                |                  |                 |
| <300                   | 6,807 31.3        | 13,943 68.7      | 20,750 26.1      |
| 300-700                | 10,271 49.9       | 10,299 50.1      | 20,570 24.7      |
| 700-1,700              | 12,398 59.7       | 8,364 40.3       | 20,762 24.9      |
| ⩾1,700                 | 12,138 60.1       | 8,054 39.9       | 20,192 24.3      |

COPD, chronic obstructive pulmonary disease. Immune deficiency: conditions that suppress the immune function due to underlying disease and/or therapy, i.e., people receiving chemotherapy, HIV infection. Expenses for specialist medical care: total amount spent in the 12 months before the start of the vaccination campaign. Percentages refer to the row total, except for Total column that refers to column total.
Table 3. Crude and adjusted incidence rate ratios of death by season in LHU 9, Treviso, Veneto Region, Italy 2014–2017.

| Vaccinated vs Unvaccinated | Univariable analysis | Multivariable analysis |
|-----------------------------|----------------------|------------------------|
|                             | Crude IRR 95% CI      | p-value                | Adjusted IRR 95% CI | p-value |
| Crude IRR                   | 95% CI                | p-value                | 95% CI                | p-value |
|                             |                      |                        |                      |        |
| **2014-2015**               |                      |                        |                      |        |
| Influenza                   | 1.30 (1.14–1.48)     | <0.001                 | 0.67 (0.58–0.77)     | <0.001 |
| Post-influenza              | 1.57 (1.33–1.84)     | <0.001                 | 0.81 (0.69–0.97)     | 0.020  |
| Summer                      | 1.44 (1.23–1.69)     | <0.001                 | 0.74 (0.62–0.87)     | <0.001 |
| Pre-influenza               | 1.63 (1.38–1.94)     | <0.001                 | 0.85 (0.71–1.02)     | 0.087  |
| **2015-2016**               |                      |                        |                      |        |
| Influenza                   | 1.20 (1.06–1.37)     | 0.005                  | 0.63 (0.55–0.72)     | <0.001 |
| Post-influenza              | 1.53 (1.30–1.80)     | <0.001                 | 0.79 (0.66–0.94)     | 0.009  |
| Summer                      | 1.66 (1.42–1.94)     | <0.001                 | 0.87 (0.73–1.03)     | 0.111  |
| Pre-influenza               | 1.75 (1.47–2.07)     | <0.001                 | 0.92 (0.77–1.11)     | 0.379  |
| **2016-2017**               |                      |                        |                      |        |
| Influenza                   | 1.17 (1.02–1.34)     | 0.021                  | 0.61 (0.53–0.71)     | <0.001 |
| Post-influenza              | 1.55 (1.32–1.82)     | <0.001                 | 0.83 (0.70–0.98)     | 0.011  |
| Summer                      | 1.67 (1.41–1.98)     | <0.001                 | 0.91 (0.76–1.09)     | 0.290  |
| Pre-influenza               | 1.72 (1.44–2.06)     | <0.001                 | 0.93 (0.77–1.13)     | 0.468  |
| Sex                         |                      |                        |                      |        |
| Female                      | 1.00                 |                        | 1.00                 |        |
| Male                        | 1.20 (1.15–1.26)     | <0.001                 | 1.49 (1.42–1.56)     | <0.001 |
| **Age group (years)**       |                      |                        |                      |        |
| 65-69                       | 1.00                 |                        | 1.00                 |        |
| 70-74                       | 1.51 (1.36–1.69)     | <0.001                 | 1.26 (1.10–1.43)     | <0.001 |
| 75-79                       | 2.83 (2.57–3.12)     | <0.001                 | 2.15 (1.89–2.43)     | <0.001 |
| 80-84                       | 5.40 (4.91–5.93)     | <0.001                 | 3.95 (3.50–4.47)     | <0.001 |
| 85-89                       | 10.27 (9.36–11.26)   | <0.001                 | 8.27 (7.31–9.36)     | <0.001 |
| ≥90                         | 21.87 (19.96–23.96)  | <0.001                 | 21.11 (18.59–23.97)  | <0.001 |
| N. of chronic underlying conditions |          |                        |                      |        |
| 0                           | 1.00                 |                        | 1.00                 |        |
| 1                           | 1.57 (1.43–1.72)     | <0.001                 | 1.12 (1.01–1.23)     | 0.030  |
| 2                           | 2.59 (2.37–2.83)     | <0.001                 | 1.42 (1.29–1.58)     | <0.001 |
| 3                           | 3.71 (3.39–4.07)     | <0.001                 | 1.66 (1.49–1.84)     | <0.001 |
| ≥3                          | 7.44 (6.81–8.12)     | <0.001                 | 2.37 (2.13–2.64)     | <0.001 |
| Pneumococcal vaccination    | 0.23 (0.21–0.26)     | <0.001                 | 0.85 (0.74–0.98)     | 0.028  |
| Expenses for specialist medical care (Euros) | 0.100 |        | 1.00 |        |
| <300                        | 1.00                 |                        | 1.00                 |        |
| 300-700                     | 1.30 (1.19–1.42)     | <0.001                 | 0.98 (0.90–1.08)     | 0.743  |
| 700-1,700                   | 1.85 (1.71–2.01)     | <0.001                 | 1.16 (1.06–1.28)     | 0.002  |
| ≥1,700                      | 5.91 (5.50–6.35)     | <0.001                 | 3.49 (3.19–3.81)     | <0.001 |

Expenses for specialist medical care: total amount spent in the 12 months before the start of the vaccination campaign. CI, confidence interval. Periods were defined as follows: influenza, December 15–March 31; post-influenza, April 1–June 30; summer, July 1–September 30; pre-influenza, October 1–December 14. IRRs (incidence rate ratios) were obtained from a zero-inflated Poisson regression model.

compared to unvaccinated was lower during influenza period (IRR 0.63, 95% CI 0.58–0.69, p < .001) and increased progressively in the other non-influenza periods [IRR ranged from 0.81 (p < .001) to 0.90 (p = .054)] (Figure 1A). Considering only the influenza period, when including an interaction term between influenza vaccination administration (yes/no) and sex (male/female), age groups (≤74, 75–84, ≥85 years old) and pneumococcal vaccination (yes/no) we found that vaccination, having adjusted for all the previously described characteristics, had similar protective effect in all age groups and in vaccinated/unvaccinated people with pneumococcal vaccine (Figure 1B). Regarding sex, although in both groups influenza vaccination was estimated to be protective for the risk of death, the magnitude of the effectiveness was significantly different (IRR = 0.55, 95% CI 0.48–0.63 in males vs 0.67 95% CI 0.59–0.75 in females, p = .028). Crude hospitalization (at least one per period/year) rates were higher among vaccinated individuals (Table 4). When adjusting for possible confounding factors, vaccination was associated with a 12-16% reduction (p < .01) in the influenza-related hospital admission rates during the influenza season (Table 4). Conversely, no effect was found in pre- and post-influenza season as well as during summer (except in pre-influenza period during 2014–2015 season). Similarly, to death analysis, being male, older, with more chronic conditions, and greater expenses for medical care were all conditions significantly associated with an increased risk of hospital admission, while a lower risk was found among pneumococcal vaccine recipients (Table 4).

**Risk of hospitalization**

Hospital admissions for all-causes were more frequent among vaccinated (32,612) as compared to the unvaccinated subjects (23,714), as well as for those influenza-related (11,712 versus 6,643) (Table S4).
and 0.79 (95% CI 0.72–0.87, p < .001) for elderly ≥85 years; differences were detected between who received (IRR 1.24, 95% CI 0.96–1.60, p = .101) and not received (0.65, 95% CI 0.53–0.80, p < .001) pneumococcal vaccination.

Lower risks of hospitalization in vaccinated subjects were detected for all identified influenza-related causes during influenza season (Table 5). Specifically, vaccination was associated with 34% reduction in hospitalization rate for influenza (IRR 0.66 95%CI 0.52–0.83, p < .001), 22% for pneumonia (IRR 0.78 95%CI 0.70–0.87, p < .001), 14% for respiratory causes (IRR 0.86 95%CI 0.77–0.96, p = .006), and 12% for cardiovascular diseases (IRR 0.88 95%CI 0.81–0.95, p = .001) (Figure 1D).

**Subgroup analysis**

Subgroup analysis, which considered only subjects who contributed to all three cohorts, highlighted that the influenza vaccination in any of the previous two seasons lowered both the mortality and influenza-related hospitalization rates in vaccinated as compared to unvaccinated subjects (Supplementary Table S5). Specifically, during influenza season 2016/17 the flu vaccination was associated with 66% reduction in mortality rates (IRR 0.34 95%CI 0.27–0.43, p < .001) in previously immunized subjects, whereas no effect was found in individuals who did not receive any vaccine in the previous 2 years (adjusted IRR 0.95 95%CI 0.65–1.39, p = .781). Similarly, vaccination was associated with 33% reduction in influenza-related hospitalization rates (adjusted IRR 0.67 95%CI 0.57–0.79, p < .001) in previously immunized subjects, while a not significant effect was observed in patients with no previously vaccination.

**Discussion**

The present retrospective cohort study was aimed at evaluating vaccination coverage and vaccine effectiveness in preventing all-cause deaths and hospital admissions attributable to influenza in the elderly population living in an area of North-Eastern Italy, in the 2014/2015-2016/2017 seasons. Vaccination coverage in this area was around 50% in all three seasons, a value very close to the national one (see Table 1). In the multivariable analysis evaluating possible determinants of receiving influenza vaccination, we found that the IRR of vaccine uptake was significantly higher in males than in females, in older people, in people with chronic conditions, with higher annual expenses for specialist medical cares (considered as a further proxy of health status), and who received pneumococcal vaccination. Of note, in the univariable model, pneumococcal vaccination was associated with a lower risk to receive the influenza vaccination; indeed, subjects
immunized with anti-pneumococcal vaccine were younger and with less co-morbidity as compared to those who were not immunized. Therefore, after adjusting for confounding variables the risk to be vaccinated was higher in those who received pneumococcal vaccination compared to unvaccinated ones.

Furthermore, although there was a statistically significant increase of the adjusted IRR in 2016/2017 compared to 2014/2015 the magnitude of increase was very small (IRR 1.03) and not really significant in terms of public health impact. There was also a significant and independently effect of the GP in the vaccination coverage, although no age and sex of the GP was associated with the vaccine uptake. These results are consistent with other studies conducted in other countries.  

Moreover, our data showed that influenza vaccination was usually received by the same individuals who were vaccinated in the previous seasons. This is in line with
a recent systematic review on factors influencing flu vaccination behavior, which include previous vaccination history as one of the key factors, together with age, poor health status, medical service use, receiving knowledge/information from healthcare professionals. Therefore, adjusting for negative and positive confounding factors through multivariable analysis should minimize this potential bias, to make sure that the observed differences in the occurrence of selected outcomes in vaccinated and unvaccinated subjects were due to the effect of the vaccine and did not reflect baseline differences between the two groups.

Regarding the effectiveness on reducing the risk of death (any cause) and the risk of influenza-related hospitalization, we found that, adjusting simultaneously for other individual characteristics, influenza vaccination was significantly associated with lower mortality and influenza-related hospitalization rates, and the benefit was found for all the discharge diagnoses including, influenza, pneumonia, respiratory, and cardiovascular diseases. Moreover, repeated influenza vaccination in the previous seasons influenced positively the vaccine effectiveness in the elderly. This is in line with recent published cohort studies in Stockholm County, Sweden that used similar outcomes as those reported in our study, and with a test negative design conducted in Valencia where the outcome was represented by confirmed influenza cases. In both studies as well as in a recent meta-analysis, no negative effects of repeated seasonal vaccination were seen across more seasons, which strengthens the recommendation that persons belonging to this age group should be vaccinated yearly. Male sex, older age, more chronic conditions, and greater annual expenses for medical cares were significantly associated with an increased risk for both outcomes (death and hospitalization), while a lower risk was found among pneumococcal vaccine recipients. Of note, after adjusting for confounding factors, vaccination was associated with a reduction in the hospital admission rates only during the influenza season, whereas a lower, but still present, reduction in risk of all-cause mortality was found also in noninfluenza periods, suggesting that additional frailty indicators (i.e., severity of chronic conditions, perceived health status, socio-economic status, behavior-related factors) could be necessary to eliminate possible unknown biasing factors; however, these are not usually included in standard administrative healthcare databases. In the absence of phase III trials using clinical endpoints, non-experimental designs to evaluate vaccine effects are often used, although methods to reduce potentially confounding factors should be considered. Indeed, according to the European Medicines Agency Guideline on influenza vaccine, secondary outcomes should address the ability of vaccines to prevent pneumonia and influenza-related hospitalization (associated with respiratory or cardiac disease) as well as all cause of deaths. Therefore, in order to control for differences in health status and health-seeking behavior in vaccinated compared with unvaccinated individuals, information on potentially confounding factors has been collected, including chronic diseases, pneumococcal vaccination, and healthcare utilization indicated by the expenses for specialist medical care. We were able to collect the most important known confounding factors except for the severity of chronic diseases, socioeconomic status, and antiviral drug use. Moreover, negative confounding may occur, as high-risk groups are more likely to be vaccinated and therefore reduce IVE. Conversely, positive confounding may occur as a result of a 'healthy vaccine effect'. People with a healthy lifestyle are more likely to accept/request vaccination, thus leading to an increase of measured IVE. Vaccine coverage has been found to be low in frail elderly patients; consequently, there may be relatively fewer severely ill patients in the exposed. Therefore, adjusting for negative and positive confounding factors through multivariable analysis should minimize this potential bias, to make sure that the observed differences in the occurrence of selected outcomes in vaccinated and unvaccinated subjects were due to the effect of the vaccine and did not reflect baseline differences between the two groups.

During the study different viruses circulated. In the 2014/15 period, A/H1N1 and A/H3N2 co-circulated and the season was characterized by a very high incidence of influenza-like-illnesses (ILI) and Intensive Care Unit (ICU) confirmed cases, especially in ≥65 years old individuals, with a mismatch between the A/H3N2 circulating virus and that included in the seasonal vaccine formulation. In Veneto Region, among severe acute respiratory infections (SARI) cases, A/H3N2 was predominant. During the following 2015/16 season, the co-circulation of A and B viruses was observed with a lower IVE estimate for influenza A(H1N1)pdm09, with respect to previous season due to the emerging genetic variant 6B.1. In Veneto Region, most ILI and SARI cases were infected with A/H3N2 virus. Moreover, during this season, the antigenic match between circulating strains (Victoria lineage) and vaccine composition (Yamagata lineage) did not fit for B. However, the detection rate of influenza type B virus among elderly in Veneto Region was low, in line with previous studies. In 2016/17 period, A/H3N2 virus predominated, and the season was characterized by a very high incidence of ILI and ICU confirmed cases, due to differences in glycosylation between A/H3N2 egg-adapted vaccines and circulating strains.

Many previous studies examined IVE by analyzing a single or more seasons, with heterogeneous results. Recent observational studies in elderly adults have estimated that the adjuvanted vaccine provided significant protection against influenza-related hospitalization and that may further reduce influenza and pneumonia hospitalizations by an estimated 25% above those prevented by nonadjuvanted vaccine. In a study conducted in another north-eastern Italian area during 2016/17 season, it was found no significant effect of influenza vaccination in the elderly on the likelihood of hospitalization or death from pneumonia and influenza, indicating that some residual confounding might exist. However, another study conducted during 2014/15 season in the same Italian Region of the previous study showed that the overall risk of death was 18% lower among vaccinated compared to unvaccinated subjects (21% for pneumonia and influenza). A recent published test negative case-control study conducted in Italy during the 2016/17 season, to estimate vaccine effectiveness in preventing severe influenza in hospitalized elderly, showed a good adjusted IVE of the MF59-adjuvated vaccine against A(H1N1)pdm09 strains and a moderate adjusted IVE against B strains. A study in US showed that vaccination in people with type 2 diabetes was associated with lower admission rates for pneumonia or influenza (IRR 0.85), and acute cardiovascular events (IRR 0.70 for stroke, 0.78 for heart failure). In a study conducted in New Zealand from 2012 to 2015, influenza
vaccination was associated with a 59% reduction in the risk of influenza-associated intensive care unit admissions among hospitalized influenza confirmed cases.\textsuperscript{54} Finally, a multicentre case–control study conducted in 11 European countries estimated that in the 2015–16 influenza season vaccination prevented approximately half of the hospitalized laboratory-confirmed influenza cases among the elderly population.\textsuperscript{55}

In interpreting our results, we need to consider some limitations. Relating to the representativeness of the study population and thus the generalizability of results, the study covered a part of a North-East Region of Italy and not the entire country. Vaccinated subjects were identified only by general practitioners’ medical records; indeed, currently does not exist a national influenza vaccination registry, and GP captured influenza vaccination data through a process in which data were initially recorded on paper and subsequently manually entered into a database; therefore, if some individuals were vaccinated outside GP practices these were considered unvaccinated. However, being the elderly individuals vaccinated free of charge, the proportion of those who paid out-of-pocket for influenza vaccine is likely to be negligible. All cases did not receive a laboratory-confirmed diagnosis of influenza; moreover, since specific causes of death were not available for all patients, only death for all-causes was considered as outcome. Since the exact vaccination date was not always available, it was not possible to define vaccinated as those subjects with an influenza vaccine administration >14 days before outcome onset. Finally, other possible factors associated with the evaluated outcomes, not considered in this analysis, could have affected the estimated IVE.

Conclusions

Study results suggest that vaccination remains the most effective preventive measure against severe influenza, among elderly people. Our findings confirm that influenza vaccination is associated with a lower risk of influenza-related complications, indicating the benefit of flu vaccination in the elderly. Further strategies should be considered for improving influenza vaccine coverage, especially among subgroups with a higher risk of more serious events. Therefore, efforts should be focused on improvement of the immunization programs as important instrument of prevention.

Authors’ contributions

CP, SB, PP, and MR conceived the idea and the study design, collected data, and revised the manuscript. CP, SB, and PP performed the statistical analyses. SB and PP drafted the manuscript. AB contributed to the circulating influenza virus strain analysis and revised the manuscript. CR contributed to critical review. All authors approved the manuscript.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. WHO - Influenza (Seasonal). [accessed 2019 September 18] https://www.who.int/news-room/fact-sheets/detail/influenza-seasonal.
2. Mertz D, Kim TH, Johnstone J, Lam -P-P, Science M, Kuster SP, Fadel SA, Tran D, Fernandez E, Bhatnagar N, Loeb M. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061. doi:10.1136/bmj.f5061.
3. Rothenberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008;121(4):258–64. doi:10.1016/j.amjmed.2007.10.040.
4. Preaud E, Durand L, Macaboo B, Farkas N, Sloesen B, Palache A, Shupo F, Samson SL. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health. 2014;14:813. doi:10.1186/1471-2458-14-813.
5. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorne C, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010; 2:CD004876.
6. Council of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination. Off J European Union. Luxembourg: Publications Office of the European Union; 2009. http://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32009H1019&from=EN
7. Vaccines against influenza WHO position paper – November. 2012. Wkly Epidemiol Rec. 2012;87(47):461–76.
8. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination in Europe - Overview of vaccination recommendations and coverage rates in the EU member states for the 2012-13 influenza season. Stockholm (Sweden): ECDC; 2015 Jan. [accessed 2019 September 18] http://ecdc.europa.eu/en/publications/Publications/Seasonal-influenza-vaccinationEurope-2012-13.pdf.
9. Ministero della Salute. Coperture vaccinali antinfluenzali. [Ministry of health, influenza vaccine coverage]. [accessed 2019 September 18] http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area=influenza&menu=vuoto.
10. Ministero della Salute. Piano Nazionale Prevenzione Vaccinale 2016-2018. [Ministry of health, national vaccination prevention plan 2016-2018]. http://www.sitip.org/formazione/linee-guida/107-linee-guida-raccomandate/159-piano-nazionale-prevenzione-vaccinale-pnv2016-2018.
11. Zhu W, Wang C, Wang BZ. From variation of influenza viral proteins to vaccine development. Int J Mol Sci. 2017;18(7):1554. doi:10.3390/ijms18071554.
12. WHO. Global epidemiological surveillance standards for influenza. 2012. [accessed 2019 September 18] https://www.adnkronos.com/r/Pub/AdnKronos/Assets/PDF/piano_prevenzione_vaccini.pdf.
13. Rümke HC, Richardus JH, Rombo L, Pauksens K, Plaßmann G, Durand C, Devaster JM, Dewé W, Oostvogels L, Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis. 2013;13:348. doi:10.1186/1471-2334-13-348.
14. Crocetti E, Arniani S, Bordoni F, Macioce G, Zappa M, Buatti E. Effectiveness of influenza vaccination in the elderly in a community in Italy. Eur J Epidemiol. 2001;17(2):163–68. doi:10.1023/A:10179778420601.
15. Russo A. A population study to evaluate the efficacy of influenza vaccination, 2014-2015. Epidemiol Prev. 2015;39:234–42.
16. Gasparini R, Amicizia D, Lai PL, Rossi S, Panatto D. Effectiveness of adjuvanted seasonal influenza vaccines (Inflalex V<sup>®</sup> and Fludair<sup>®</sup>)


in preventing hospitalization for influenza and pneumonia in the elderly: a matched case-control study. Hum Vacc Immunother. 2013;9(1):144–52. doi:10.4161/hv.22231.
17. Valent F, Schiava F, Gnesutta D, Brianti G, Barbone F. Gruppo regionale influenza Friuli-Venezia Giulia. Evaluation of the effectiveness of the vaccination impact among elderly in Friuli-Venezia Giulia (Italy). Epidemiol Prev. 2005 May-Aug;29(3–4):195–203.
18. Valent F, Gallo T, Zanier L. Vaccinazione antinfluenzale e mortalità nella popolazione anziana residente in Friuli-Venezia Giulia. Uno studio di coorte nella stagione influenzale 2014-2015. Politziche Sanitarie. 2016;17:41–47.
19. Valent F, Gallo T. Influenza vaccine effectiveness in an Italian elderly population during the 2016-2017 season. Ann Istit Super Sanita. 2018;54(1):67–71. doi:10.4145/ANN_18_01_13.
20. The John Hopkins ACG* System. Decades of impact on population health research and practice. [accessed 2019 September 18]. https://www.hopkinsacg.org/.
21. ACG John Hopkins, Veneto Region. [accessed 2019 September 18]. www.acg.regione.veneto.it.
22. Leyland AH, Goldaeen H. Multilevel modelling of health statistics. New York: Wiley; 2001.
23. Bertolani A, Fattori G, Pregliasco F. The hospitalization burden of influenza: just the tip of the iceberg? Global Reg Health Technol Assess. 2018;2018:1–9.
24. Vamos EP, Pape UJ, Curcin V, Harris MI, Valabhishek M, Majeed A, Millett C. Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes. CMAJ. 2016;188(14):E342–E351. doi:10.1503/cmaj.151059.
25. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333–40. doi:10.1001/jama.292.11.1333.
26. Cameron AC, Trivedi PK. Regression analysis of count data. Cambridge, UK: Cambridge University Press; 1998.
27. Loeps T, Moerkerke B, De Smet O, Buyssse A. The analysis of zero-inflated count data: beyond zero-inflated Poisson regression. British J Math Stat Psychol. 2012;65(1):163–80. doi:10.1111/j.2044-8317.2011.02031.x.
28. Vuong QH. Likelihood ratio tests for model selection and non-nested hypotheses” (PDF). Econometrica. 1989;57(2):307–33. doi:10.2307/1912557.
29. PJ L, O’Halloran A, Ding H, Srivastav A, Williams WW. Uptake of influenza vaccination and missed opportunities among adults with high-risk conditions, united states, 2013. Am J Med. 2016;129(6):636.e1-636.e11. doi:10.1016/j.amjmed.2015.10.031.
30. Ganczak M, Gil K, Korzeń M, Bażyldy M. Coverage and influencing determinants of influenza vaccination in elderly patients in a country with a poor vaccination implementation. Int J Environ Res Public Health. 2017;14:6. doi:10.3390/ijerph14060665.
31. Ang LW, Cutter J, James L, Goh KT. Factors associated with influenza vaccine uptake in older adults living in the community in Singapore. Epidemiol Infect. 2017;145(4):775–86. doi:10.1017/S0950268816002491.
32. Kan T, Zhang J. Factors influencing seasonal influenza vaccination behaviour among elderly people: a systematic review. Public Health. 2018;156:67–78. doi:10.1016/j.puhe.2017.12.007.
33. Órquist Å, Brytting M, Leval A, Hergens MP. Impact of repeated influenza vaccinations in persons over 65 years of age: a large population-based cohort study of severe influenza over six consecutive seasons, 2011-2016. Vaccine. 2018;36(37):5556–64. doi:10.1016/j.vaccine.2018.07.052.
34. Martínez-Baz I, Navascués A, Casado I, Aguina A, Ezepeleta C, Jess Castilla J. Remaining effect of influenza vaccines received in prior seasons. J Infect Dis. 2019 May 20. doi:10.1093/infdis/jiz266.
35. Ramsay LC, Buchan SA, Stirling RG, Cowling BJ, Feng S, Kwoh JC, Welshovsky BF. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med. 2019 Jan 10;17(1):9. doi:10.1186/s12916-018-1239-8.
36. Hak E, Verheij T, Grobbée DE, Nichol KL, Hoes AW. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Community Health. 2002;56(12):951–55. doi:10.1136/jech.56.12.951.
37. European Medicine Agency. Committee for Medicinal Products for Human Use. Guideline on influenza vaccines. EMA/CHMP/VWP/457259/2014.
38. European Centre for Disease Prevention and Control. Technical document 2009. Protocol for cohort database studies to measure pandemic and seasonal influenza vaccine effectiveness in the European union and European economic area member states. Stockholm, Sweden, ECDC; 2009. [accessed 2019 September 18]. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0907_TER_Influenza_AH1N1_Measuring_Influenza_Vaccine_Effectiveness_Protocol_Cohort_Database_Studies.pdf.
39. Fireman B, Lee J, Lewis N, Bembo B, Van Der Laan M, Baxter R. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol. 2009;170(5):650–56. doi:10.1093/aje/kwp175.
40. Jackson LA, Nelson JC, Benson P, Neuzil KM, Reid RJ, Psaty BM, Heckbert SR, Larson EB, Weiss NS. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol. 2005;35(2):345–52. doi:10.1093/ije/dyi275.
41. McElhaney JE, Andrew MK, McNeil SA. Estimating influenza vaccine effectiveness: evolution of methods to better understand effects of confounding in older adults. Vaccine. 2017. doi:10.1016/j.vaccine.2017.09.084.
42. Istituto Superiore di Sanità. Sorveglianza virologica dell’influenza, stagione influenzale 2014-2015 [Influenza virological surveillance, 2014-2015 season], [accessed 2019 September 18], http://old.iss.it/binary/fluv/cont/Rapporto_2014_2015.pdf.
43. Istituto Superiore di Sanità. La sorveglianza dei casi gravi e decessi da influenza confermata in Italia nella stagione 2014-15 [Surveillance of influenza-confirmed serious cases and deaths in Italy in the 2014-15 season], [accessed 2019 September 18], https://www.epicentro.iss.it/vaccini/CasiGravi2015.
44. Veneto Region. Rapporto sull’andamento epidemiologico dell’influenza nella Regione Veneto, stagione 2014-2015 [Report on the epidemiological trend of influenza in the Veneto Region, 2014-2015 season], [accessed 2019 September 18], https://www.regione.veneto.it/web/sanita/sanita-influenza-archivio.
45. Istituto Superiore di Sanità. Sorveglianza virologica dell’influenza, stagione influenzale 2015-2016 [Influenza virological surveillance, 2015-2016 season], [accessed 2019 September 18], http://old.iss.it/binary/fluv/cont/Rapporto_2015_2016.pdf.
46. Kissling E, Valenciano M, Pozo F, Vilcu AM, Reus A, Rizzo C, Larrauri A, Horváth JK, Brytting M, Doménguez I, Koryczynska M. 2015/16 I-MOVE/I-MOVE＋ multicentre case-control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. Influenza Other Respir Viruses. 2018;12(4):423–37. doi:10.1016/j.influenza.2015.12.007.
47. Veneto Region. Rapporto sull’andamento epidemiologico dell’influenza nella Regione Veneto, stagione 2015-2016 [Report on the epidemiological trend of influenza in the Veneto Region, 2015-2016 season].
48. Panatto D, Signori A, Lai PL, Gasparini R, Amicizia D. Heterogeneous estimates of influenza virus types A and B in the elderly: results of a meta-regression analysis. Influenza Other Respir Viruses. 2018;12(4):423–37. doi:10.1016/j.influenza.2015.12.007.
49. Veneto Region. Rapporto sull’andamento epidemiologico dell’influenza nella Regione Veneto, stagione 2015-2016 [Report on the epidemiological trend of influenza in the Veneto Region, 2015-2016 season].
Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A. 2017;114(47):12578–83. doi:10.1073/pnas.1712377114.

51. Veneto Region. Rapporto sull’andamento epidemiologico dell’influenza nella Regione Veneto, stagione 2016-2017 [Report on the epidemiological trend of influenza in the Veneto Region, 2016-2017 season]. [accessed 2019 September 18]. https://www.regione.veneto.it/web/sanita/influenza-archivio.

52. Tsai TF. Fluad®-MF59®-Adjuvanted influenza vaccine in older adults. Infect Chemother. 2013 Jun;45(2):159–74. doi:10.3947/ic.2013.45.2.159.

53. Bella A, Gesualdo F, Orsi A, Arcuri C, Chironna M, Loconsole D, Napoli C, Orsi GB, Manini I, Montomoli E, Alfonsi V. Effectiveness of the trivalent MF59 adjuvanted influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017-2018 season. Expert Rev Vaccines. 2019 Jun;13:1–9. doi:10.1080/14760584.

54. Thompson MG, Pierse N, Sue Huang Q, Prasad N, Duque J, Claire Newbern E, Baker MG, Turner N, McArthur C. Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012-2015. Vaccine. 2018;36(39):5916–25. doi:10.1016/j.vaccine.2018.07.028.

55. Rondy M, Larrauri A, Casado I, Alfonsi V, Pitigoi D, Launay O, Syrjänen RK, Gefenaite G, Machado A, Vučina VV, Horváth JK. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. Euro Surveill. 2017;22:30. doi:10.2807/1560-7917.ES.2017.22.30.30580.